Saturn V Capital Management LP
CIK 1964437 · View on SEC EDGAR ↗
- Portfolio value
- $697.5M
- Positions
- 23
- As of
- June 30, 2026
Portfolio value QoQ: +26.3% 13F does not disclose cash
- Top 10 holdings weight
- 75.59%
- Top 25 holdings weight
- 100.00%
- Positions above 1%
- 20
- Effective number of positions
- 14.2
Based on 13F long-equity holdings only (cash, bonds, shorts not disclosed)
Turnover Q2 2026: 8.1% Est. buys $95,529,252 · sells $50,619,107
Median holding: 3.0 quarters Tracked Q4 2024–Q2 2026 · 48.9% still held
- New positions
- 3
- Increased
- 13
- Decreased
- 6
- Closed
- 1
On this page
- Performance vs S&P How this manager's 13F portfolio performed against the S&P 500.
- Sector breakdown How the portfolio splits across market sectors.
- Portfolio Every stock this institution reports holding, from its latest 13F.
- High-conviction bets The holdings this manager is most concentrated in.
- Biggest new bets Brand-new positions opened in the latest quarter.
- Top moves The biggest position increases and decreases this quarter.
- Exited positions Positions the manager fully sold out of last quarter.
Performance vs S&P 500
Annualized: +92.5% · S&P 500: +18.0%
Approximates a buy-and-hold portfolio built from quarterly SEC 13F snapshots. Excludes cash, short positions, options/derivatives, and non-13(f) securities — reflects the disclosed long-equity book only, not total fund AUM. SEC filing lag is up to 45 days; this is not a real-time-copyable timing.
Priceable coverage: 99.2% · Options excluded: 0.0%
Sector breakdown
Full portfolio 23 positions
| Type | Streak | 8Q trend | |||||
|---|---|---|---|---|---|---|---|
| AMLX Amylyx Pharmaceuticals, Inc. - Common Stock | $83,048,854 | 11.91% | 4,624,101 | $22,585,452 | Up ×1 | ||
| ALMS Alumis Inc. - Common Stock | $82,040,566 | 11.76% | 2,915,443 | $11,498,854 | Down ×1 | ||
| ABVX Abivax SA - American Depositary Shares | $69,143,950 | 9.91% | 518,865 | $8,714,750 | Down ×3 | ||
| PCVX Vaxcyte, Inc. - Common Stock | $49,579,891 | 7.11% | 852,914 | $1,666,336 | Up ×6 | ||
| IMMX Immix Biopharma, Inc. - Common Stock | $48,028,403 | 6.89% | 4,658,429 | $14,379,844 | Up ×2 | ||
| PHVS Pharvaris N.V. - Ordinary Shares | $45,442,339 | 6.52% | 1,314,122 | $11,502,733 | Up ×3 | ||
| JAZZ Jazz Pharmaceuticals plc - Ordinary Shares | $38,781,230 | 5.56% | 160,938 | $7,973,453 | Down ×3 | ||
| CELC Celcuity Inc. - Common Stock | $38,742,669 | 5.55% | 370,318 | $6,566,146 | Up ×1 | ||
| IRON Disc Medicine, Inc. - Common Stock | $38,378,752 | 5.50% | 524,730 | $9,610,484 | Up ×2 | ||
| CADL Candel Therapeutics, Inc. - Common Stock | $34,027,966 | 4.88% | 3,303,686 | $19,834,685 | Up ×1 | ||
| XFOR X4 Pharmaceuticals, Inc. - Common Stock | $32,565,512 | 4.67% | 6,973,343 | $5,899,564 | Up ×2 | ||
| MNPR Monopar Therapeutics Inc. - Common Stock | $28,885,858 | 4.14% | 311,976 | $9,949,009 | Down ×1 | ||
| DYN Dyne Therapeutics, Inc. - Common Stock | $23,486,920 | 3.37% | 1,057,493 | $5,962,299 | Up ×1 | ||
| TRVI Trevi Therapeutics, Inc. - Common Stock | $19,620,602 | 2.81% | 1,052,043 | Up ×1 | |||
| ZURA Zura Bio Limited - Class A Ordinary shares | $12,396,602 | 1.78% | 2,101,119 | $7,993,840 | Up ×1 | ||
| SGMT Sagimet Biosciences Inc. - Series A Common Stock | $11,439,766 | 1.64% | 1,479,918 | Up ×1 | |||
| OCS Oculis Holding AG - Ordinary shares | $9,499,286 | 1.36% | 684,880 | $-4,241,389 | Up ×1 | ||
| IKT Inhibikase Therapeutics, Inc. - Common Stock | $7,854,184 | 1.13% | 3,869,056 | $1,363,596 | Up ×2 | ||
| VIR Vir Biotechnology, Inc. - Common Stock | $7,852,852 | 1.13% | 770,643 | Up ×1 | |||
| IVVD Invivyd, Inc. - Common Stock | $7,321,432 | 1.05% | 8,392,288 | $-6,912,377 | Down ×1 | ||
| ANRO Alto Neuroscience, Inc. Common Stock | $4,824,857 | 0.69% | 182,829 | $2,824,159 | Up ×1 | ||
| MSLE Satellos Bioscience Inc. - Common Stock | $2,721,250 | 0.39% | 350,000 | $750,750 | |||
| OVID Ovid Therapeutics Inc. - Common Stock | $1,783,631 | 0.26% | 663,060 | $-7,466,368 | Down ×1 | ||
| No matches | |||||||
Conviction holdings
Positions increased for 3+ consecutive quarters.
Share counts are as reported in 13F filings (not split-adjusted)
Biggest new bets
New positions opened this quarter, largest first.
Top movers (QoQ)
| Security | Action | Shares Δ | Value Δ |
|---|---|---|---|
| AMLX | Bought more | +274K | +$22.6M |
| CADL | Bought more | +407K | +$19.8M |
| IMMX | Bought more | +965K | +$14.4M |
| PHVS | Bought more | +113K | +$11.5M |
| ALMS | Trimmed | -287K | +$11.5M |
| MNPR | Trimmed | -34K | +$9.9M |
| IRON | Bought more | +75K | +$9.6M |
| ABVX | Trimmed | -24K | +$8.7M |
| ZURA | Bought more | +1.4M | +$8.0M |
| JAZZ | Trimmed | -2K | +$8.0M |
Exited positions
Includes corporate events (mergers, delistings) — not all exits are sells
Closed positions reflect 13F reporting changes; for index managers these are often mechanical (delisting, M&A, index rebalancing), not active decisions.
| Security | Quarter | Shares before | Value before | Price since exit |
|---|---|---|---|---|
| COGT | June 30, 2026 | 626,635 | $24,119,181 | -6.6% |
| CGON | Dec. 31, 2025 | 579,895 | $23,358,171 | 88.5% |
| XENE | Dec. 31, 2025 | 503,701 | $20,223,595 | 34.3% |
| OCUL | March 31, 2026 | 1,504,880 | $18,269,243 | 33.1% |
| MRUS | Dec. 31, 2025 | 184,135 | $17,336,310 | No longer tracked |
| LENZ | Dec. 31, 2025 | 368,176 | $17,149,638 | -70.1% |
| CYTK | March 31, 2025 | 348,364 | $16,387,043 | 92.8% |
| CRGX | March 31, 2025 | 1,007,677 | $14,530,702 | No longer tracked |
| MLTX | Sept. 30, 2025 | 290,784 | $13,725,005 | 121.2% |
| NBIX | Sept. 30, 2025 | 58,181 | $7,312,770 | 9.7% |
| CNTA | March 31, 2026 | 282,692 | $7,070,127 | No longer tracked |
| ASND | Sept. 30, 2025 | 38,191 | $6,591,767 | 29.7% |
| ARGX | Sept. 30, 2025 | 10,285 | $5,669,298 | 40.5% |
| SNDX | Sept. 30, 2025 | 500,551 | $4,687,660 | 28.7% |
| NAMS | Dec. 31, 2025 | 153,147 | $4,355,501 | -20.2% |
| IRWD | March 31, 2025 | 814,533 | $3,608,381 | 189.1% |
| CRNX | June 30, 2025 | 59,017 | $1,979,430 | 194.7% |
| IVA | March 31, 2026 | 283,166 | $1,316,722 | -14.6% |
| CTNM | Sept. 30, 2025 | 319,348 | $1,267,812 | 36.2% |
| REPL | Sept. 30, 2025 | 128,917 | $1,197,639 | 249.0% |
| KALV | Sept. 30, 2025 | 62,793 | $709,875 | No longer tracked |
| INZY | June 30, 2025 | 499,254 | $454,321 | No longer tracked |
| MBX | March 31, 2025 | 18,000 | $331,740 | 798.7% |
| SLN | Sept. 30, 2025 | 34,737 | $201,475 | 155.5% |